MONTREAL (CANADA) – April 29, 2022 – Inversago Pharma Inc. , a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announced that François Ravenelle, PhD, Chief Executive Officer, will take part to one-on-one meetings with investors during the Morgan Stanley Private Company Biotech Corporate Access Day.
This day-long event will be held virtually on Tuesday, May 3, 2022.
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).
– 30 –
Contact
François Ravenelle, PhD
Chief Executive Officer
Inversago Pharma Inc.
info@inversago.com
